Abstract:Background:
JWCAR029 is a CD19-directed 4-1 BB CAR T cell product, of which CD4 and CD8 CAR T cells are produced together and transfused in non-fixed ratio. A phase I, single-arm, open label study was conducted to evaluate the safety and efficacy of JWCAR029 in patients (pts) with relapsed or refractory B-NHL. Previously, preliminary data in six pts (Yan et al, Blood 2018 132:4187) showed high response rates and favorable safety profiles of JWCAR029. Herein, we presented the data of the Phase I … Show more
“…These low rates were obtained by using a protocol‐defined toxicity management algorithm, did not result from significant tocilizumab or corticosteroid use, which was required in only 28.8% and 15.2% of treated patients, respectively. Pharmacokinetic parameters showed similar expansion and contraction kinetics over time as has been reported by several groups 20‐24 …”
Section: Discussionsupporting
confidence: 83%
“…Pharmacokinetic parameters showed similar expansion and contraction kinetics over time as has been reported by several groups. [20][21][22][23][24] This trial is the first to randomize patients between two CAR-T dosing groups, low dose (100 × 10 6 ) and high dose (150 × 10 6 ). While no overt improvement in response rates was observed, all severe CRS and NT events occurred with the higher dose.…”
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
“…These low rates were obtained by using a protocol‐defined toxicity management algorithm, did not result from significant tocilizumab or corticosteroid use, which was required in only 28.8% and 15.2% of treated patients, respectively. Pharmacokinetic parameters showed similar expansion and contraction kinetics over time as has been reported by several groups 20‐24 …”
Section: Discussionsupporting
confidence: 83%
“…Pharmacokinetic parameters showed similar expansion and contraction kinetics over time as has been reported by several groups. [20][21][22][23][24] This trial is the first to randomize patients between two CAR-T dosing groups, low dose (100 × 10 6 ) and high dose (150 × 10 6 ). While no overt improvement in response rates was observed, all severe CRS and NT events occurred with the higher dose.…”
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.